Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT03817125 - Nivolumab + SER-401 vs Nivolumab & Melanoma (cutaneous)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background

Modulating the gut microbiota holds potential for enhancing the response to immune-checkpoint blockade (ICB) therapies. Despite this promise, there is a notable absence of precision biomarker-driven, placebo-controlled trials in this area (1)

Study overview

It is a multicenter and randomized phase I trial in patients with Immune Checkpoint Inhibitors (ICIs) Therapy-naïve metastatic melanoma (cutaneous) evaluating SER-401 (week 2) + Nivolumab + SER-401 (week 3-11) + Nivolumab (week 12-48) after [vancomycin](brain://PG6ZNnPiD02IvGZcRzjR…

References (Sources)

Randomized Placebo-Controlled, Biomarker- Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
Glitza et al. 2024 Cancer Discov 14: 1161-75

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!